BioCentury
ARTICLE | Finance

Andera looks early for cancer immunotherapy

How Grey Wolf's A round helped Andera diversify its cancer immunotherapy portfolio

February 16, 2019 12:17 AM UTC

Andera Partners changed gears with an early investment in preclinical company Grey Wolf Therapeutics to diversify its cancer immunotherapy portfolio. Along with Canaan Partners, Andera backed a £10 million ($12.9 million) series A for Grey Wolf, announced with the closing of a second tranche on Feb. 11.

The first £5 million ($6.5 million) tranche closed in 2018, one of three cancer immunotherapy investments Andera made that year. The others were late-stage buy-ins, as Andera led a $70 million series B for Crescendo Biologics Ltd. and a £65 million ($84.3 million) series B for Artios Pharma Ltd. (see “Andera Leads Crescendo’s $70M Series B” & “Artios Raises £65M Series B”)...